

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 41/00, 47/48</b>	<b>A1</b>	(11) International Publication Number: <b>WO 95/32001</b> (43) International Publication Date: 30 November 1995 (30.11.95)
--	-----------	---

(21) International Application Number: PCT/EP95/01938  
(22) International Filing Date: 22 May 1995 (22.05.95)  
(30) Priority Data: FI94A000095 23 May 1994 (23.05.94) IT

(71) Applicant (for all designated States except US): L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI [IT/IT]; Strada Statale, 67, I-50018 Scandicci (IT).

(71)(72) Applicant and Inventor: NERI, Giovanni [IT/IT]; Via Roma, 26, I-53100 Siena (IT).

(72) Inventor; and  
(75) Inventor/Applicant (for US only): RONCUCCI, Gabrio [IT/IT]; Via Mensanello, 34, I-53034 Colle Val d'Elsa (IT).

(74) Agent: GERVASI, Gemma; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milano (IT).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: PHOTODYNAMIC CONJUGATES WITH BIOCIDAL PROPERTIES

(57) Abstract

Photodynamic conjugates consisting of a carrier molecule and of an organic molecule able to efficiently produce singlet oxygen after irradiation are described. Said conjugates are useful either for therapeutical or diagnostic aim.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

## PHOTODYNAMIC CONJUGATES WITH BIOCIDAL PROPERTIES

FIELD OF THE INVENTION

The present invention concerns conjugates consisting of a carrier molecule linked to an organic molecule able to efficiently produce singlet oxygen after irradiation suitably derivatized as to react with an amino or thiol group of the carrier molecule. Said conjugates are able to work out a biocidal action on various kinds of cells, either in vivo or in vitro, once activated with radiations in the near UV; they may be used either for therapeutical or diagnostic aim.

10 PRIOR ART

It is known that organic molecules, able to efficiently produce singlet oxygen as a result of irradiation, have photoenhanced biocidal activity. The biocidal activity of the molecules shows itself against essentially every living form such as viruses, fungi, bacteria, invertebrates, vertebrates, eukaryote cells [see J.B. Hudson et al.: Pharm. Ther. 49, 181 (1991); J.B. Hudson et al.: Chemosphere 19, 1329 (1989); J.B. Hudson et al.: Chemosphere 18, 2317 (1989)].

The biocidal properties make these molecules extremely interesting for a great number of applications in therapy. However the practical application of the above mentioned molecules is strongly limited because they are powerful contact allergens and cause, once administered and irradiated, erythemas, pruritus and hyperpigmentation for periods of weeks and months [see G.H.N. Towers et al.: Contact Dermatitis 5, 140 (1978); W. Rampone et al.: J. Invest. Dermatol. 87, 354 (1986)].


25 It is thus obvious the interest to develop compounds which, while keeping the desired biocidal capabilities, do not show the undesirable side

- 2 -

effects.

# DETAILED DESCRIPTION OF THE INVENTION

Now it has been surprisingly discovered that it is possible to remove the negative effects related to the use of the above mentioned molecules keeping unaltered their biocidal properties by conjugating the organic molecule able to produce efficiently singlet oxygen after irradiation to a carrier molecule able to direct it on a definite biological target. According to a particular embodiment of the present invention the organic molecule able to produce efficiently singlet oxygen after irradiation is a molecule having general formula (I)



(I)

wherein  $Z_1$ ,  $Z_2$ ,  $Z_3$  equal or different one another are S or O, suitably derivatized as to react with an amino or thiol group of the carrier molecule.

According to a further particular embodiment of the invention the organic molecule able to produce efficiently singlet oxygen as a result of irradiation is the 2,2':5',2"-terthiophene (hereinafter abbreviated as  $\alpha$ -T) molecule having formula (I) in which  $Z_1=Z_2=Z_3=S$ .

According to the invention the carrier molecule is selected from the group consisting of: antibodies (native, monoclonal or recombinant) peptides, haptamers (nucleic acids with the capability of a selective bond toward a target), sugars, or other analogous carriers able to direct the derivative having formula (I) toward a biological target as for

- 3 -

example the avidin-biotin conjugate.

In particular the terthienyl compound may be derivatized with a group able to react with amino groups (for example side chains of lysine residues in peptides or proteins), with thiol groups (for example side chains of cysteine), with suitably modified saccharide residues of the carrier molecule or with avidin and/or biotin utilizing the functional groups present in these molecules; these solutions allow to conjugate the terthienyl derivative with a wide spectrum of different molecules.

The derivatization of the terthienyl compound is carried out preferably in position 2.

When the terthienyl derivative is linked to Avidin and/or Biotin the conjugate object of the present invention may be directly formed in vivo separately administering the part formed by Biotin bound to the carrier molecule and the part formed by Avidin bound to the  $\alpha$ -T derivative or vice versa.

The utility of these systems consists in the fact that they allow the administration of an inferior quantity of the  $\alpha$ -T derivative without lowering the potential therapeutic efficiency of the molecule, making it available various  $\alpha$ -T derivatives conjugated both to Biotin and Avidin.

In this case the  $\alpha$ -T system is mediated by the Avidin-Biotin bond ( $K_{aff} = 10^{15}$ ) which makes it possible the immobilization of the  $\alpha$ -T molecule on the pathogenic agent in subsequent steps by binding the Avidin to the antibody and thereafter administering the  $\alpha$ -T molecule linked to Biotin or by using a biotinylated antibody, then giving Avidin and finally  $\alpha$ -T linked to Biotin according to a three step protocol, or allows an amplification of the administrable  $\alpha$ -T quantity (thanks to the tetravalency of the Avidin molecule).

- 4 -

The conjugate according to the invention, as previously defined, may be used either for the topical treatment of superficial diseases (melanomas, eye diseases, fungineous or viral skin infections) or vehiculated by intramuscular or intravenous way.

- 5 In the case of topical administration the compositions commonly provided for this aim will be used such as: ointments, creams, unguents containing the compound having formula (I) in combination with the suitable diluents known in the state of the art for this kind of applications.

The composition will be directly applied in the area of interest, then  
10 the part will be washed in order to reduce the presence of  $\alpha$ -T near healthy cells but without compromising its localization on the pathogen and finally submitting the part to irradiation with light of the near ultraviolet (about 360 nm) or simply exposing the treated part to the sunlight.

- 15 In the case of the injections the active product will be dissolved in the suitable liquids physiologically acceptable for the preparation of injectable solutions.

In this case the subsequent irradiation, required to activate the molecule, may be carried out using optical fibres and the correlated  
20 surgical techniques.

Some examples of preparation of products according to the invention are described hereinafter for explicative but not limitative aim.

In particular, in the examples 1-7 afterwards reported the preparation of derivatives of the 2,2':5',2"terthienyl suitably functionalized in order  
25 to covalently react with amino groups present on the carrier molecule is described; in the examples 9 - 11 the functionalization is carried out to allow the analogous reaction with thiol groups present on the carrier

- 5 -

molecule; in the example 12 the functionalization is carried out to allow the analogous reaction with saccharide groups.


In the example 13 the functionalization is carried out to allow the same reaction on tyrosine or histidine residues.

- 5 Examples 14 and 15 refer to Biotin derivatives preparation. Examples 16 - 19 refer to conjugates preparation according to the invention; and finally the examples 20 - 26 describe tests on the biocidal activity of the considered products.

$\alpha$ -T DERIVATIVES REACTIVE TO AMINO GROUPS AND CORRESPONDING INTERMEDIATES

10 Example 1

5-Formyl-2,2':5',2"-terthiophene [( $\alpha$ -T)-CHO].




- 6 -

dry evaporated. The residue is purified by column chromatography (silica gel, benzene) to give a gold-yellow crystalline solid, m.p.: 137-8 °C.


### Example 2

Methyl(E)-3-(2,2':5',2''-terthien-5-yl)propenoate.





- 7 -




- 8 -

constituted for the major part of dicyclohexylurea, is filtered out and washed with a little dichloromethane. The solutions are pooled, dry evaporated in order to remove the DMF, then the solid is treated with dichloromethane. The residual dicyclohexylurea, which is separated again, is removed and the solution evaporated after being water washed and dehydrated. A yellow solid is obtained.

NMR (CDCl<sub>3</sub>, 200 MHz): 7.24-7.01 (m, 7H, α-T); 7.73 (d, 1H, =CH-COOCH<sub>3</sub>); 6.18 (d, 1H, α-T -CH=); 2.84 (s, 4H, succinimide).

#### Example 5

10 N-5-methyl-(2,2':5',2"-terthien-5-yl)-L-proline.



0.58 mmol of aldehyde described in the example 1 are suspended in 30 ml of methanol at room temperature and 1.15 mmol of proline and 300 mg of molecular sieves are added to the suspension.

After having saturated the reaction mixture with nitrogen, 100 mg of sodium cyanoborohydride are added and the mixture stirred for 12 h at room temperature. At the end of the reaction the solvent is dry evaporated and the greyish residue, after being treated with water and upon the elimination of the molecular sieves, is filtered.

A light yellow solid is obtained; m.p.: 157-163 °C (dec.) (MeOH-DMF)

20 darkening after light exposure.

- 9 -

Analysis:  $C_{18}H_{17}NO_2S_{3.1/2}H_2O$  PM = 384.5


Calculated: C: 56.63 H: 5.02 N: 5.09

Found: C: 56.88 H: 4.74 N: 5.10

NMR (DMSO, 200 MHz): 7.52-6.96 (m, 7H,  $\alpha$ -T); 4.04 (AB sys, 2H,  $CH_2$ -N);  
 5 3.51-3.37 (m, 2H, Pro); 3.15-3.00 (m, 1H, Pro); 2.7-2.52 (m, 1H, Pro);  
 2.21-2.0 (m, 1H, Pro); 2.0-1.55 (m, 2H, Pro).

#### Example 6

N-5-methyl-(2,2':5',2''-terthien-5-yl)-L-proline-N-hydroxy  
 succinimido ester [ $\alpha$ -TPOSu].



10 0.13 mmol of hydroxysuccinimido are added, at once, to 0.13 mmol of the  
 compound obtained in the previous example, suspended in a solution of DMF  
 3 ml and dichloromethane 5 ml. The suspension is sonicated to allow for  
 maximum solubilization of the reactants and added, at room temperature,  
 with 0.13 mmol of dicyclohexyl-carbodiimide previously solubilized in 5  
 15 ml of dichloromethane.


The reaction mixture is stirred for 20 h at room temperature. The  
 obtained solid is removed by filtration and the dry evaporated residual  
 solution yielded a light yellow oil which solidified by adding  
 petroleum ether to give the wanted product.

20 NMR ( $CDCl_3$ , 200 MHz): 7.26-6.87 (m, 7H,  $\alpha$ -T); 4.10 (AB sys, 2H,  $CH_2$ -N);  
 3.78 (dd, 1H, H-CO-Pro); 3.10 (m, 1H, Pro); 2.82 (m, 1H, Pro); 2.84 (s,

- 10 -


4H, succinimide); 2.39-1.80 (m, 4H, Pro).

In the same way the N-5-methyl-(2,2':5',2''-terthien-5-yl)-L-proline-N-hydroxysulphosuccinimido ester was prepared.



#### Example 7

5 N-methyl-N-5-methyl-(2,2':5',2''-terthien-5-yl)glycine.



0.89 mmol of the aldehyde according to the example 1 are suspended in 50 ml of a methanol/acetic acid 99:1 mixture, previously deaerated and saturated with nitrogen. 3 equivalents of sarcosine and 0.5 equivalents of sodium cyanoborohydride are added at room temperature under stirring.

10 The stirred reaction is sheltered from light for 24 h; during this time an abundant yellow precipitate is formed.

The solid so obtained, after being separated by filtration, is dried and crystallized from isopropyl alcohol/DMF; m.p.: 230 °C (dec.).

Elementary Analysis:  $C_{16}H_{15}NO_2S_3$  PM = 349.47

15 Calculated: C: 54.98 H: 4.32 N: 4.00

Found: C: 55.02 H: 4.27 N: 4.31

Proceeding according to example 6 the following compounds were also

- 11 -

obtained:

N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)glycine-N-hydroxy-succinimido ester

N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)glycine-N-hydroxy-

5 sulfosuccinimido ester

N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)monomethyl

succinimide amide hydrochloride N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-3-p-azido-phenyl-propanamide


N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-3-(2'-nitro-5'-

10 azido)phenyl propanamide.

#### DERIVATIVES OF THE $\alpha$ -T REACTIVE TO THIOL GROUPS AND RELATED INTERMEDIATES

##### Example 8

5-methylaminomethyl-2,2':5',2"-terthiophene.



1.44 mmol of the aldehyde described in example 1 are suspended in 50 ml of degassed methanol and added with 6 equivalents of methylamine  
15 hydrochloride.

0.5 equivalents of  $\text{NaBH}_3\text{CN}$  are added to the suspension and the mixture stirred at room temperature under nitrogen.

The reaction mixture is stirred for further 2 h sheltered from light then, the resulting suspension is partially evaporated.

20 The product purified by thin-layer chromatography (silica gel, chloroform: ethanol 93:7) allows to obtain a light yellow solid.


- 12 -

NMR (CDCl<sub>3</sub>, 200 MHz): 7.35-6.82 (m, 7H, α-T); 3.93 (s, 2H, α-T-CH<sub>2</sub>-); 2.51 (s, 3H, N-CH<sub>3</sub>).

Example 9

N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-bromoacetamide

5 [(α-T)-BrAc].



0.24 mmol of the amine obtained in the example 5 are solubilized in 50 ml of deaerated dichloromethane and kept under nitrogen.

To the solution cooled to 0 °C and sheltered from light 0.24 moles of N-hydroxysuccinimido ester of bromoacetic acid are added under stirring.

10 After 30' the temperature is left rising to room values and kept at such values for 2 h.

The crystalline residue which results from solvent evaporation is treated with petroleum ether and purified by thin-layer chromatography (silica gel, chloroform). The light yellow crystalline solid obtained has

15 m.p.: 107-9 °C.

Analysis: C<sub>16</sub>H<sub>14</sub>BrNOS<sub>3</sub> PM = 412.36

Calculated: C: 46.60 H: 3.44 N: 3.39

Found: C: 46.80 H: 3.37 N: 3.42


NMR (CDCl<sub>3</sub>, 200 MHz): 7.23-6.88 (m, 7H, α-T); 4.72 and 4.68 (s, 2H, α-T-CH<sub>2</sub>); 3.10 and 3.02 (s, 3H, N-CH<sub>3</sub>); 3.95 and 3.89 (s, 2H, CO-CH<sub>2</sub>-).

20 Example 10

S,S - pyridyl- dithio-N-methyl-N-5- methyl- (2,2':5',2"-terthien-5-yl)-

- 13 -

propanamide.



0.20 moles of the amine obtained in the example 5 are solubilized in 30 ml of distilled, degassed and saturated with nitrogen dichloromethane. The solution is cooled to 0 °C and, sheltered from light and under stirring, added with 0.22 mmol of S,S-pyridyl-dithiopropionic-N-5 hydroxysuccinimido ester (SPDP) acid. After 1 h the solution is left rising to room temperature and stirred for further 48 h. The solvent is then fully evaporated and the residual product purified by column chromatography (silica gel, chloroform/methanol 98:2).

Analysis:  $C_{22}H_{20}N_2S_5O$  PM = 488.7


10 Calculated: C: 54.06 H: 4.12 N: 5.73

Found: C: 53.57 H: 4.11 N: 5.72

NMR ( $CDCl_3$ , 200 MHz): 7.22-6.85 (m, 7H,  $\alpha$ -T); 4.65 and 4.57 (s, 2H,  $CH_2$ -N); 2.93 and 3.00 (s, 3H, N- $CH_3$ ); 8.44 (ddd, 1H, Py); 7.75-7.58 (m, 3H, Py); 3.13 (t, 2H,  $CH_2$ ); 2.78 (t, 2H,  $CH_2$ ).

#### 15 Example 11

N- methyl-N-5-methyl-(2,2':5',2''- terthien-5-yl)-4- (N-maleimidomethyl)cyclohexyl-1-carboxamide.



- 14 -

0.27 mmol of amine prepared according to the example 8 are solubilized in 2 ml of DMF.


The solution is diluted with 30 ml of dichloromethane nitrogen saturated and cooled to 0 °C. 0.30 mmol (1.1 equivalents) of succinimidyl-4-(N-5 maleimidomethyl)-cyclohexano-1-carboxylate (SMCC) are added to the solution under stirring. Then the reaction mixture is warmed to 35 °C for 12 h and subsequently added with further 0.09 mmol of SMCC.

After 24 h of stirring the solvent is evaporated and the residual solid is purified by column chromatography (silica gel; CHCl<sub>3</sub>) obtaining a 10 crystalline solid.

#### α-T DERIVATIVES CONJUGABLE TO SACCHARIDIC RESIDUES

##### Example 12

N<sup>α</sup>-methyl-N<sup>α</sup>-5-methyl- (2,2': 5', 2"-terthien-5-yl) glycyl hydrazide.



0.5 mmol of the product obtained as described in the example 7 (N - 15 methyl-N-5-methyl-(2,2': 5', 2"-terthien-5-yl)glycine-N-hydroxysuccinimido ester) solubilized in 5 ml of anhydrous THF, are added drop by drop to 5 ml of a solution of hydrazine hydrate in 5% THF at 0 °C, under vigorous stirring.

After 4 h the reaction mixture is evaporated and the oily residue



- 15 -

purified by column chromatography (silica gel;  $\text{CHCl}_3/\text{CH}_3\text{OH}$  95:5) to give a light yellow solid; m.p.:158 °C. NMR ( $\text{CDCl}_3$ , 200 MHz): 7.18-6.71 (m, 7H,  $\alpha$ -T); 3.65 (s, 2H,  $\text{CH}_2$ ); 2.27 (s, 3H,  $\text{N-CH}_3$ ); 3.08 (s, 2H,  $\text{N-CH}_2\text{-CO}$ ); 8.01 (s, br ex, 1H, NH); 3.75 (s, br ex, 2H,  $\text{NH}_2$ ).

$\alpha$ -T DERIVATIVES CAPABLE OF REACTING WITH THYROSINE AND HYSTIDINE RESIDUES

5 Example 13


N-methyl-N-5-methyl(2,2':5',2"-terthien-5-yl)-p-aminobenzamide

$\alpha$ -T DERIVATIVES LINKED TO BIOTIN

Example 14

N,N'-dimethyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-N-biotinyl-1,2-

10 diaminoethane



0.2 mmol of the aldehyde obtained in the example 1 are suspended in 30 ml of a  $\text{CH}_3\text{OH}/\text{CH}_3\text{COOH}$  (99:1) mixture.

2 Equivalents of N,N'-dimethyl-N'-biotinyl-1,2-diaminoethane and 0.5 equivalents of sodium cyanoborohydride are added to the nitrogen saturated

15 suspension.

The suspension is stirred for 48 h then the solvent is evaporated, the residue is treated with water, filtered and purified by HPLC.

- 16 -

Example 15

N-methyl-N-(2,2':5',2"-terthien-5-yl)-methyl-biotinamide

91 mg (0.44 mmoles) of dicyclohexylcarbodiimide are added to a suspension of 107 mg (0.44 mmoles) of Biotin and 55 mg (0.48 mmoles) of N-5 hydroxysuccinimide in DMF (1.5 ml).

The mixture is stirred at room temperature for 20 h and thereafter 140 mg (0.48 mmoles) of N-methyl-N-(2,2':5',2"-terthiophen-5-yl)methylamine solved in 10 ml DCM are added.

After 3 h at room temperature the formed dicyclohexylurea is filtered off and the organic phase is washed with H<sub>2</sub>O and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent is eliminated by evaporation and the obtained solid is purified by HPLC (H<sub>2</sub>O/TFA 0.1% - MeOH).

Functionalization of the carrierExample 16

15 Conjugate ( $\alpha$ -T)-concanavalin A.

100  $\mu$ l of a solution of  $\alpha$ TPOSu 16.5 mg/ml are slowly added to 2 mg of concavalin A (produced by Sigma Company) (final conc.  $3.5 \times 10^{-3}$  mmol) solubilized in 0.25 ml of 100 mM phosphate buffer (pH 8). The obtained suspension is gently stirred for a night at 4 °C in the dark.

20 After centrifugation, the supernatant, constituted of terthienylated Concanavalin A is purified by gel filtration on Sephadex G25 collecting the fractions showing a characteristic fluorescence.

The terthienylated concanavalin A has been characterized in terms of moles of  $\alpha$ -T per mole of protein and this value turned out to be equal to

25 10.

- 17 -

Example 17

Conjugate ( $\alpha$ -T)-succinyl Concanavalin A (SuConA).

The terthienylation reaction of the SuConA has been worked out in a way analogous to what reported in the example 13.

- 5 The moles of  $\alpha$ -T per mole of protein ratio turned out to be equal to 1.5, thus lower than the conjugate with concanavalin A owing to a lower availability of the amino groups.

Example 18

Conjugate ( $\alpha$ -T)-Avidin.

- 10 100  $\mu$ l of solution 1.5<sup>4</sup> mg/ml in DMSO of aTPOSu (example 6) are added to 2 mg of avidine (Boheringer product) solubilized in 0.5 ml of 100 mmol phosphate buffer (pH 8). The suspension is gently stirred for one night at 4 °C in the dark, centrifuged, then the conjugate is purified by gel filtration on Sephadex G10<sup>®</sup> eluting with 100 MM phosphate buffer (pH 8).
- 15 collecting the fluorescent fractions.

The ratio between the number of moles of  $\alpha$ -terthienyl introduced per mole of Avidin has been obtained from the molar extinction coefficient value determined for the  $\alpha$ -terthienyl derivative compared to the proteic one and turned out to be equal to 7.

20 Example 19

Bovine Serum Albumin (BSA) has been dissolved in PBS at the concentration of 50 mg/ml; the aldehyde obtained according to the example 1 and the product obtained in the example 6 ( $\alpha$ TPOSu) have been dissolved in dimethyl sulfoxide (DMSO) at a concentration of 2 mg/ml.

- 25 In two parallel experiments 1.8 ml of BSA solution were allowed to react for one night at 4 °C in the dark with 0.2 ml of the two above mentioned solutions of the  $\alpha$ -T derivatives. The day after a small aliquot of the

- 18 -

two reaction products has been purified by gel filtration on PD-10 (Pharmacia) columns, in order to separate the terthienylated BSA from the terthienyl reactants if in excess. During the gel filtration it has been observed that the yellowish colouring of the  $\alpha$ -T derivative quantitatively co-migrated with the proteic fraction, showing that the terthienyl compounds had reacted in quantitative manner with the protein. The raw reaction products and the products purified by gel filtration have finally been analysed by electrophoresis on acrylamide gel in native conditions, using fluorescein labelled BSA.

10 The bands in the gel have been visualized by irradiation with ultraviolet light and then the gel has been photographed in these conditions. Such analysis revealed that the terthienylation of the BSA with the two reactants gave a fluorescence well detectable by the two bands characteristic of the BSA on native gel, which migrated in a analogous way compared with the two bands of the fluorescein labelled BSA.

#### Example 20

The monoclonal antibody 225-28S [Natali P.G. et al. J. Nat. Cancer Inst. 73, 13-24 (1984)] has been functionalized with  $\alpha$ TPOSu at the amino-group residues using the following protocol.

20 50  $\mu$ l of a solution of  $\alpha$ TPOSu 14 mg/ml in DMSO (final conc.  $1.3 \times 10^{-3}$  mmol, 200 equivalents) have been slowly added, by a variable volume pipet, to 1 mg of monoclonal 225-28S at a concentration of 5 mg/ml in 100 mM phosphate buffer, pH 8.

The so obtained milky suspension is gently stirred for 2 h at room temperature in the dark.

25 After this time the solid still present is removed by centrifugation and the solution of the labelled antibody is purified by gel filtration on

- 19 -

Sephadex G25<sup>®</sup>.

The monoclonal labelling has been verified recording the UV spectrum of the pooled fractions obtained by the filtering purification, which shows two absorption maxima both at 280 nm and 360 nm and which are  
5 respectively due to the protein and to the presence of alfa terthienyl derivative.

From the measurement of the recorded UV absorptions (taking into account the value of  $\epsilon^{360}=27000 \text{ LM}^{-1}\text{cm}^{-1}$  for the alfa terthienyl derivative used) it is possible to estimate a labelling ratio of 3 moles of  $\alpha$ -T per mole  
10 of protein.

#### Example 21

A recombinant anti-lysozyme antibody, HyHEL-10 [Lavoie T.B. et al.: J. Immunol. 148,503-513 (1992)], in scFv configuration [(G.Winter and C. Milstein: Nature, 349, 293 (1991); D. Neri, M. Momo, T. Prospero, G.  
15 Winter (1995) High affinity antigen binding by chelating recombinant antibodies (CRABS) - J. Mol. Biol., 246, 367-377)] in which a cysteine residue has been cloned at the C-terminal end of the molecule as single site of thiol-specific functionalization (in the following denoted as antibody scFv-cys), has been derivatized with the bromo acetamide  
20 compound described in the example 9 in the following way.

The antibody scFv-cys at a concentration of. 1 mg/ml in PBS has been reduced for 15 minutes by addition of dithiothreitol (DTT) at a final concentration of 0.1 mM.

0.1 ml of a solution of bromo acetamide prepared according to the example  
25 9 in DMSO (2 mg/ml; final concentration 0.48 mM) have been added to 0.9 ml of the reduced antibody solution, in order to have enough terthyenil derivative for both saturating the DTT present in solution and

- 20 -

functionalizing the cysteines of the molecules of scFv-Cys. The reaction has been carried out for 2 h in ice, then stopped by addition of 0.1 ml of 100 mM DTT.

The terthienylated antibody has been purified by gel filtration on PD-10 (Pharmacia) column and the occurred terthienylation has been checked out by running a gel electrophoresis on acrylamide in denaturing conditions. The gel irradiated with ultraviolet light showed the presence of a fluorescent band of molecular weight of about 30000 dalton.

In the same way were prepared:

- 10 - Mouse anti Herpes simplex Virus 1 and 2 antibody
  - $\alpha$  terthienyl conjugate
  - Human anti Herpes simplex Virus 1 and 2 antibody Fab fragment-  $\alpha$ -terthienyl conjugate
  - Mouse anti Rubella virus  $\alpha$  - terthienyl conjugate

## 15 BIOCIDAL EFFECT

### Example 22

Antibacteric activity of substituted terthienyl derivatives.

The bacterial strain TG1 (Escherichia Coli) containing a plasmid with the gene of resistance to ampicillin has been grown in medium 2xTY-100  $\mu$ g/ml ampicillin till reaching a value of  $A^{600}=0.5$ .

Then the cells have been centrifuged, resuspended in PBS (10 times the original volume;  $A^{600}=0.05$ ) in Petri dishes. To each dish a dilution 1:1000 of a stock solution of photosensitizer [PBS (negative control),  $\alpha$ -T or ( $\alpha$ -T)-CHO (according to the example 1)] in DMSO (1 mg/ml) has been added. The photosensitizer final concentration was therefore 1  $\mu$ g/ml. The Petri dishes have been irradiated with gentle stirring by a UVP BLB lamp and plated in serial dilutions (10  $\mu$ l and 100  $\mu$ l) on plates of agar +

- 21 -

2xTY + 100 µg/ml ampicillin.

The bacteria photo-killing efficacy, not only by the α-T but also by the (α-T)-CHO derivative is easily detectable according to the number of colonies formed on plate after irradiation as shown in following Table I

TABLE I

	Colonies number	
	10 µl	100 µl
Negative control	10 <sup>5</sup>	10 <sup>6</sup>
(α-T)-CHO	50	500
α-T	6	48

- 5 As shown the formil substituted terthienyl derivative keeps its biocidal activity.

#### Example 23

Antitumoral activity of terthienylated antibodies.

- 10 The cellular line COLO-38, derived from a Human melanoma, and the monoclonal 225-28S terthienylated antibody according to example 18 [and in the following denoted as IgG-(α-T)] are used.

- The α-T molecule/IgG molecule ratio has been estimated to be 1.6 on the basis of the conjugate absorption at 360 nm, using the absorption coefficient  $\epsilon^{360}=27000 \text{ LM}^{-1} \text{ cm}^{-1}$  for α-T, assuming quantitative recover  
15 of the protein used in the terthienylation, or from the molar extinction coefficients values  $\epsilon^{360}=27000 \text{ LM}^{-1} \text{ cm}^{-1}$  and  $\epsilon^{280}=2700 \text{ LM}^{-1} \text{ cm}^{-1}$  as a contribution of the absorption at 280 nm typical of the protein under examination.

- 20 COLO-38 cells, grown in RPMI medium added with 10% FETAL CALF SERUM (FCS), have been washed and parallely incubated in Petri dishes with IgG(α-T) (5 µM), IgG alone (5 µM), IgG-(α-T) not correlated (5 µM) or

- 22 -

only with the medium in the negative controls.

The dishes have been irradiated at 350 nm for 30 minutes, then washed and left to incubate for 24 h in RPMI added with 10% FCS.

The dead and living cells percentage has been finally determined in the following way.

The cells have been incubated with propidium bromide and fluorescein diacetate, then washed and analysed with a confocal BioRad MRC 600<sup>®</sup> microscope. The propidium bromide intensely colours the dead cells DNA in red, while the fluorescein diacetate is efficiently hydrolyzed to a green fluorescent product by esterases present in living cells.

In this way the analysis by two wavelengths laser confocal microscopy leads to the number of dead and living cells within the population.

	% Killing	
	COLO 38	HT 29
IgG-( $\alpha$ -T)	>90	12
IgG	8	14
PBS	6	10

The results above related clearly show that the melanoma cells are efficiently killed by IgG( $\alpha$ -T) but neither by not labelled IgG nor in the negative control made with HT 29 cells. In particular comparing the "killing" caused by IgG-( $\alpha$ -T) over HT 29 cells it is clear that the  $\alpha$ -T localization, due to carrier molecule conjugate specific targeting, has as consequence the selective killing of the targeted cells.

#### Example 24

A monoclonal antibody anti *Candida albicans* is functionalized with  $\alpha$ TPOsu prepared as described in Example 6 at its amino residues according to the following procedure: 200 equivalents of  $\alpha$ TPOsu solubilized in 100  $\mu$ l of



- 23 -

N-methyl-pyrrolidone where added to 0.32 mg of antibody in 100  $\mu$ M Phosphate pH = 8.5. The resulting solution was incubated 2 h at 37°C then the resulting labelled antibody was purified by gel-filtration on Sephadex G25<sup>®</sup>.

- 5 The presence of  $\alpha$ -T bounded to the protein was confirmed from the UV-spectrum of the fractions eluted from the column at the highest absorbing values at 280 nm and 360 nm (which refer respectively to the protein and the  $\alpha$ -terthienyl derivative). The protein recover is practically 100% and the labelling ratio is about 5 moles of  $\alpha$ -T for each mole of protein.

10 Example 25

Antifungine activity of vehiculated  $\alpha$ -T.

A: Photokilling of *Candida albicans* (C.a.) and *Saccaromices cerevisiae* (S.c.) cells mediated by lectines labelled with  $\alpha$ -T.

Following the previously described procedures (see examples 16 and 17)

- 15 the product obtained in the example 6 ( $\alpha$ PTOSu) has been conjugated to concanavalin A (ConA) and to succinyl-concanavalin A (SuConA), a concanavalin derivative able to bind a great variety of fungi, but very less susceptible of agglutination with respect to concanavalin A.

*Saccharomyces cerevisiae* and *Candida albicans* cultures, grown in Sabourad

- 20 Dextrose broth at 37 °C for 4 h, were diluted up to a concentration of about  $2.5 \times 10^4$  cells/ml.

Aliquots of 0.1 ml of these suspensions have been added in the sterile micro-plates wells by multi-channel pipet. Then 0.1 ml of solution having suitable concentration containing the terthienylated derivative to test

- 25 have been added in the various wells.

The tested compounds were the  $\alpha$ -T, ConA-( $\alpha$ -T), SuConA-( $\alpha$ -T), ConA, SuConA, IgG-( $\alpha$ -T) antimelanoma (see the example 23) at the  $\alpha$ -terthienyl

- 24 -

final concentration equal to  $3 \times 10^{-6}$  M/l.

Samples of *Candida albicans* and *Saccaromices cerevisiae* suspensions containing no terthienyl-derivative acted as reference in the experiment. Suspensions of *Candida albicans* and *Saccaromices cerevisiae* thus prepared have been incubated in the dark for 0.5 h, then irradiated at 350 nm for 30 minutes. Aliquots of *Candida albicans* and *Saccaromices cerevisiae* treated as above said and, respectively, non-treated were deposited on Petri plates containing Sabouraud Dextrose Agar. The plates were incubated in the dark for 24 h at 33° and the growth of the treated and non-treated samples was evaluated.

Compound	Final conc. $\alpha$ -T (M/l)	Final. Conc. ConA/SuConA (M/l)	% Growth of col. C.a. and S.c. (non-treat. = 100)	
ConA- $\alpha$ -T	$3 \times 10^{-7}$	$3 \times 10^{-8}$	0	0
SuConA- $\alpha$ T	$5 \times 10^{-7}$		10	5
$\alpha$ -T	$4 \times 10^{-6}$		90	100
ConA		$3.4 \times 10^{-5}$	100	100
SuConA		$1.4 \times 10^{-5}$	100	100
IgG anti melan. $\alpha$ -T	$6.5 \times 10^{-6}$		80**	

\*\* The colonies number increases up to 100 by washing the cells with a physiologic solution containing 0.01% Tween 20.

These results show that non-labelled lectines have no toxicity and non-vehiculated  $\alpha$ -T can not bind to the cells and are not able to exert the cytotoxic action.

On the other hand lectines labelled with  $\alpha$ -T bind specifically and are stable to washing showing a good photo-sensibilization after irradiation. Finally non-related proteins labelled with  $\alpha$ -T, (IgG anti melanoma - $\alpha$ -T)

- 25 -

which can not bind on the cells, show no photosensibilization capacity.

B: Photokilling mediated by specific  $\alpha$ -T labelled anti *Candida albicans* antibodies.

The specific photosensibilization was evaluated on *Candida albicans* cell.

- 5 A monoclonal antibody anti *Candida albicans* (C.a.) was labelled with  $\alpha$ -TOSu according to the previously described procedure.

The terthienylated antibody, named IgG anti C.a.- $\alpha$ -T, containing 5 moles of  $\alpha$ -T per mole of IgG, was used for the test of specific killing of this mycete.

- 10 To a suspension of *Candida albicans* cells, (ATCC 10231 in PBS pH 7.4, 0.5 McFarland), aliquots of  $\alpha$ -T (final conc  $4 \times 10^{-6}$  M/l), IgG anti C.a.- $\alpha$ -T (final conc.  $6.5 \times 10^{-7}$  M/l of  $\alpha$ -T), IgG anti HSV- $\alpha$ -T (final conc.  $6.5 \times 10^{-6}$  M/l of  $\alpha$ -T) and IgG anti C.a. non-terthienylated (same conc. as in the conjugates rapresenting the control), were added. The cells were  
15 incubated in the dark for 30', the supernatants eliminated and the cells washed three times with a physiologic solution and finally collected by centrifugation in order to eliminate the  $\alpha$ -T or the terthienylated-antibody excess.

- The cells suspension in PBS was irradiated with a 360 nm light for 30'  
20 and 20  $\mu$ l aliquots deposited on Sabouraud-Agar plates which were incubated in the dark for 24 h at 33°C. The number of developed colonies was compared to the control (PBS).

- 26 -

	Final Conc. (M/l)	% colonies growth (control = 100)
IgGanti C.a.- $\alpha$ -T	$6.5 \times 10^{-7}$	0
IgGanti HSV- $\alpha$ -T	$6.5 \times 10^{-6}$	85
$\alpha$ -T	$4 \times 10^{-6}$	90
IgGanti C.a.		100
PBS	0	100

The above reported results show that only the terthienylated specific antibody binds to the cell wall of C.a cells producing a photodynamic effect "in situ" after irradiation at 360 nm.

#### Example 26

- 5 The cutaneous phototoxicity of the  $\alpha$ -terthienylated derivatives was tested by treatment of the depilated skin of albino guinea pigs.

The test was performed on male guinea pigs (weight 200 - 250g) caged under controlled ventilation and at the temperature of 22°C.

- 10 On the abdomen skin of the animals, which was accurately depilated 24 hours before the test, 10  $\mu$ l of a solution of proteic conjugates linked to  $\alpha$ -T (for example ConA- $\alpha$ -T, see example 13, and IgG anti HSV1- $\alpha$ -T) were applied, maintaining similar concentration of  $\alpha$ -T.

- After 1 hour the skin was repeatedly washed (Tween 20 0.01% in PBS) and irradiated at 360 nm for 1 hour. The intensity of the erithemateous  
15 reaction was determined 48 hours after the irradiation.

- The results show that the cutaneous phototoxicity of the conjugates depends on the carrier used. If the carrier binds aspecifically, as in the case of ConA, and therefore is not totally removed by washing, only a slight decrease of the toxicity is observed after washing with a  
20 detergent.

- 27 -

Conjugates prepared starting from antibodies which can recognise selectively the pathogenic-agent, which do not bind aspecifically on the skin, are completely removed by washing and do not show a toxic reaction, confirming their importance in the treatment of cutaneous infections.

Erythema intensity

Conjugate (conc.....)	no washing	washing with detergent
ConA- $\alpha$ -T	0.62	0.28
IgG antiHSV1	0.03	0.0

- 5 Erythema intensity scale: 0 no erythema, 1 max. erythema)

The above reported examples clearly show that suitably vehiculated  $\alpha$ -T, or its structural analogues, may be used for the selective and quantitative killing of biologically and clinically relevant targets such as cancer cells, bacteria and fungi.

- 10 Moreover the viruses killing mediated by vehiculated  $\alpha$ -T, for example of the herpes virus, is particularly interesting due to the possibility to act on the infection at topical level either concerning the active principle application or for the irradiation modalities of the interested zone.


- 15 The terms "derivatized" and "functionalized" as used in the present application indicate, when referred to the terthienyl-moiety, the introduction in the molecule of groups capable of reacting with specific other groups while, when referred to a protein, indicate the introduction in the protein of the terthienyl-moiety.

- 28 -

CLAIMS

1 1. Conjugates consisting of a carrier molecule and of an organic molecule  
2 able to efficiently produce singlet oxygen after irradiation.

1 2. Conjugates as claimed in claim 1 wherein the organic molecule able to  
2 efficiently produce singlet oxygen after irradiation is a compound having  
3 formula (I)



4 where  $Z_1$ ,  $Z_2$  and  $Z_3$  equal or different one another are S or O, suitably  
5 derivatized in order to react with an amino, thiol, saccharide, hystidine  
6 and tyrosine group of the carrier molecule.

1 3. Conjugates as claimed in claim 2 wherein the compound having formula  
2 (I) is 2,2':5' 2''-terthiophene suitably derivatized in order to react  
3 with an amino, thiol or saccharide, hystidine, tyrosine groups of the  
4 carrier molecule, as well as bound to Biotin and to photoreactive side  
5 chains.

1 4. Conjugates as claimed in claim 1 wherein the carrier molecule is  
2 selected from the group consisting of antibodies, peptides, haptamers,  
3 sugars or other analogous carriers able to direct the photosensitizer  
4 molecule toward a biological target.

1 5. Conjugates as claimed in claim 4 wherein the carrier molecule is  
2 linked to the  $\alpha$ -T by an avidin-biotin complex.

1 6. Conjugates as claimed in claim 2 in which the molecule having formula  
2 (I) is derivatized in order to react with an amino group of the carrier

- 29 -

3 molecule.

1 7. Compounds having formula (I) as claimed in claim 6 represented by the  
2 following formulas:

3 (E) -3- (2,2': 5',2"- terthien-5-yl) propenoic N-hydroxy succinimido  
4 ester

5 N-(5- methyl-2,2': 5', 2"- terthien-5-yl) - 1 - proline-N-  
6 hydroxysuccinimido ester [ $\alpha$ -TPOSu]

7 N-methyl-N-(5-methyl-2,2': 5', 2"-terthien-5-yl)glycine-N-hydroxy-  
8 succinimido ester

9 N-methyl-N-(5-methyl-2,2': 5', 2"-terthien-5-yl)glycine-N-hydroxy-  
10 sulfosuccinimido ester.

11 N-5-methyl-(2,2':5',2"-terthien-5-yl)-1-proline-N-hydroxy-  
12 sulphosuccinimido ester

13 N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)monomethyl  
14 succinimidate amide hydrochloride

15 N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-3-p-azido-phenyl-  
16 propanamide

17 N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-3-(2'-nitro-5'-  
18 azido)phenyl propanamide

1 8. Conjugates as claimed in claim 2 wherein the molecule having formula  
2 (I) is derivatized in order to react with a thiol group of the carrier  
3 molecule.

1 9. Compounds having formula (I) as claimed in claim 8 represented by the  
2 following formulas:

3 N - methyl-N - (5-methyl-2,2': 5',2"-terthien-5-yl)-bromo acetamide

4 S,S - pyridyl-dithio - N- methyl- (5-methyl-2,2': 5',2"- terthien-5-yl)-  
5 propanamide.

- 30 -

6 N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-4 - (N-  
7 maleimidomethyl)cyclohexyl-1-carboxamide.

1 10. Conjugates as claimed in claim 2 wherein the molecule having formula  
2 (I) is derivatized in order to react with a saccharide group of the  
3 carrier molecule.

1 11. Compounds having formula (I) as claimed in claim 10 represented by:  
2 N<sup>α</sup>-methyl-N<sup>α</sup>-5-methyl-(2,2':5',2"-terthien-5-yl) glycylyl hydrazid.

1 12. Conjugates as claimed in claim 2 wherein the molecule having formula  
2 (I) is derivatized in order to react with a histidine or tyrosine group.

1 13. Compound having formula (I) as claimed in claim 12 represented by:  
2 N-methyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-p-aminobenzamide

1 14. Conjugates as claimed in claim 2 wherein the molecule having formula  
2 (I) is derivatized in order to react with Biotin.

1 15. Compound having formula (I) as claimed in claim 14 represented by:  
2 N,N'-dimethyl-N-5-methyl-(2,2':5',2"-terthien-5-yl)-N-biotinyl-1,2-  
3 diaminoethane;

4 N-methyl-N-(2,2':5',2"-terthien-5-yl)-methyl-biotinamide

1 16. Conjugates as claimed in claim 1 obtained by conjugating:

2 αTPOSu and concanavalin A

3 αTPOSu and succinyl-concanavalin A

4 αTPOSu and avidin

5 (α-T)-CHO and BSA

6 αTPOSu and monoclonal antibody 225-28S

8 (α-T)-BrAc and scFv-cys

9 αTPOSu and monoclonal antibody anti C. albicans

10 αTPOSu and monoclonal antibody anti Herpes simplex Virus 1 and 2

11 αTPOSu and Human monoclonal antibody anti Herpes simplex Virus 1 and 2



- 31 -

12 Fab fragment

13  $\alpha$ TPOsu and monoclonal antibody anti Rubella Virus.

1 17. Use of the conjugates as claimed in claim 1 for the preparation of  
2 antibacterial, antiviral, antifungi, and antitumoural compositions in  
3 combination with the suitable pharmaceutically acceptable excipients.

1 18. Use as claimed in claim 13 wherein the compositions are for oral,  
2 intramuscular and topical use.

1 19. Method for the treatment of bacterial, fungineous, viral and tumoural  
2 diseases wherein therapeutically effective amounts of the active product  
3 as claimed in claim 1 are administered to the patient.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 95/01938

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K41/00 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 118, no. 25, 21 June 1993 Columbus, Ohio, US; abstract no. 250762, SPIKES, JOHN D. ET AL 'Photoproperties of a mesochlorin e6-N-(2- hydroxypropyl)methacrylamide copolymer conjugate' see abstract & J. PHOTOCHEM. PHOTOBIOL., A (1993), 70(2), 163-70 CODEN: JPPCEJ; ISSN: 1010-6030, 1993	1
P, X	EP, A, 0 641 796 (UNIV BRITISH COLUMBIA) 8 March 1995 see page 12, line 29 - line 35; claims --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

13 October 1995

Date of mailing of the international search report

27. 10. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Berte, M

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/EP 95/01938

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. CONTROLLED RELEASE (1994), 29(1-2), 1-16 CODEN: JCREEC;ISSN: 0168-3659, 1994 KLYASHCHITSKY, B. A. ET AL 'Approaches to targeted photodynamic tumor therapy' see page 1	1
P,A	--- CHEMICAL ABSTRACTS, vol. 123, no. 1, 3 July 1995 Columbus, Ohio, US; abstract no. 5407, MARES, D. ET AL 'Antifungal activity of some 2,2':5',2"-terthiophene derivatives' see abstract & MYCOSES (1994), 37(9/10), 377-83 CODEN: MYCSEU;ISSN: 0933-7407, 1994	1-19
A	--- CHEMICAL ABSTRACTS, vol. 119, no. 23, 6 December 1993 Columbus, Ohio, US; abstract no. 244537, HUDSON, J. B. ET AL 'The anti-HIV activities of photoactive terthiophenes' see abstract & PHOTOCHEM. PHOTOBIOLOG. (1993), 58(2), 246-50 CODEN: PHCBAP;ISSN: 0031-8655, 1993	1-19
A	--- J. INVEST. DERMATOL., vol. 87, no. 3, September 1986 pages 354-357, WILLIAM M. RAMPONE TEL. 'CHARACTERIZATION OF CUTANEOUS PHOTOTOXICITY INDUCED BY TOPICAL ALPHA-TERTHIENYL AND U.V. RADIATION.*' cited in the application see the whole document	1,17-19
X	--- CA,A,1 173 743 (TOWERS GEORGE H N;ARNASON JOHN T; WAT CHI KIT; LAMBERT JOHN D H) 4 September 1984 see page 9, line 2; claim 2	17-19
X	--- EP,A,0 454 204 (DUPHAR INT RES) 30 October 1991	2,3,11, 13,15
Y	see claims	2,3,11, 15
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 95/01938

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 47, no. 39, 1991 OXFORD GB, pages 8443-8460, RENRO ROSSI ET AL. 'SELECTIVE AND EFFICIENT SYNTHESIS OF PHOTOTOXIC 2,2':5,2"-TERTHIOPHENE DERIVATIVES BEARING A FUNCTIONAL SUBSTITUENT IN THE 3'- OR THE 5-POSITION.' cited in the application see page 8444 -----</p>	2,3,11, 15

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/01938

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0641796	08-03-95	US-A- 4920143	24-04-90
		AT-T- 127696	15-09-95
		AU-B- 638675	08-07-93
		AU-B- 3825889	08-02-90
		EP-A- 0352076	24-01-90
		JP-A- 2149519	08-06-90
		JP-B- 7080887	30-08-95
		US-A- 5399583	21-03-95
		US-A- 5095030	10-03-92
		US-A- 5171749	15-12-92
		US-A- 5283255	01-02-94
-----			
CA-A-1173743	04-09-84	NONE	
-----			
EP-A-0454204	30-10-91	AT-T- 124394	15-07-95
		DE-D- 69110739	03-08-95
		JP-A- 4225951	14-08-92
		US-A- 5252191	12-10-93
-----			

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/01938

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: Claim 19  
because they relate to subject matter not required to be searched by this Authority, namely:  
"Remark : Although claim 19 is directed to a method of treatment of  
(diagnostic method practised on) the human/animal body the search has been  
carried out and based on the alleged effects of the compound/composition."
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such  
an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.